Jubilant Ingrevia reported a robust Q1 FY27 with revenue reaching a 15-quarter high of ₹1,300 crore, up 25% year-on-year. EBITDA and PAT also saw significant growth, driven by volume increases and better pricing across segments. The company maintained its full-year EBITDA guidance.
Detailed Coverage
Jubilant Ingrevia Reports Strong Q1 FY27 with Record Revenue
Jubilant Ingrevia's revenue reached ₹1,300 crore, a 15-quarter high, with PAT at ₹106 crore.
Reader Takeaway: Strong revenue growth and maintained EBITDA guidance are positives, but raw material volatility poses a risk.
What just happened
Jubilant Ingrevia announced its financial results for the first quarter of FY27, showcasing a significant increase in revenue, EBITDA, and Profit After Tax (PAT). Revenue for the quarter stood at ₹1,300 crore, marking a 25% year-on-year increase and the highest in 15 quarters. EBITDA grew 36% year-on-year to ₹209 crore, and PAT rose by 41% year-on-year to ₹106 crore.
Why this matters
This strong performance indicates healthy demand for Jubilant Ingrevia's products and effective execution of its business strategies. The substantial year-on-year growth across key financial metrics suggests improved operational efficiency and pricing power. Maintaining the full-year EBITDA guidance provides investors with confidence in the company's future outlook.
The backstory
Jubilant Ingrevia is a global integrated life science products and solutions provider. It operates across three key segments: Specialty Chemicals, Nutrition, and Chemical Intermediates. The company has been focusing on expanding its capacity and strengthening its Contract Development and Manufacturing Organization (CDMO) pipeline.
What changes now
The company's performance in Q1 FY27 sets a positive tone for the fiscal year. The active CDMO pipeline, with over 100 molecules and significant peak revenue potential, is a key growth driver. Operational updates, including the Niacinamide plant nearing full capacity and the upcoming commissioning of a new multipurpose plant, are expected to contribute to future growth.
Risks to watch
Management has highlighted potential headwinds such as raw material price volatility and cyclical downturns in the agrochemicals sector. Pricing pressure in base pyridine due to overcapacity in China is also a concern, although the company aims to mitigate this through downstream derivatives.
Peer comparison
Jubilant Ingrevia operates in diverse chemical segments, making direct peer comparisons challenging. However, its performance in terms of revenue growth and profitability in specialty chemicals and nutrition needs to be viewed against other companies in these specific sub-sectors within the Indian chemical industry.
Context metrics (time-bound)
- Revenue: ₹1,300 crore (Q1 FY27), up 25% YoY.
- EBITDA: ₹209 crore (Q1 FY27), up 36% YoY and 22% sequentially.
- PAT: ₹106 crore (Q1 FY27), up 41% YoY and 22% sequentially.
- CDMO Pipeline: 100+ molecules, peak revenue potential > ₹3,500 crore.
- Niacinamide plant utilization targeted at 70%+ by year-end.
- Full-year EBITDA guidance: ₹750 crore - ₹800 crore.
What to track next
Investors will be closely watching the ramp-up of the Niacinamide plant, the commissioning of the new multipurpose plant by end-2026, and the progress of the CDMO contract execution. Updates on volumes for CDMO contracts and raw material price trends will also be crucial.